Molecular imaging probes for 31P contrast
<p><sup>31</sup>P magnetic resonance has yet to realise its clinical potential principally due to the relatively low sensitivity of the <sup>31</sup>P nucleus. While <sup>31</sup>P-MRS can uniquely provide vital information regarding in vivo phosphorus met...
Päätekijä: | Tear, L |
---|---|
Muut tekijät: | Faulkner, S |
Aineistotyyppi: | Opinnäyte |
Kieli: | English |
Julkaistu: |
2018
|
Aiheet: |
Samankaltaisia teoksia
-
Glucosamine Conjugated Gadolinium (III) Oxide Nanoparticles as a Novel Targeted Contrast Agent for Cancer Diagnosis in MRI
Tekijä: T Mortezazadeh, et al.
Julkaistu: (2020-02-01) -
Magnetic Resonance Imaging Contrast Agents: A Review of Literature
Tekijä: Zahra Sahraei, et al.
Julkaistu: (2015-10-01) -
Interval between contrast administration and T1-weighted MRI for cerebral adrenoleukodystrophy: a single-case observation
Tekijä: Marco Moscatelli, et al.
Julkaistu: (2023-10-01) -
Image quality of late gadolinium enhancement in cardiac magnetic resonance with different doses of contrast material in patients with chronic myocardial infarction
Tekijä: Caterina Beatrice Monti, et al.
Julkaistu: (2020-04-01) -
Macrocyclic MR contrast agents: evaluation of multiple-organ gadolinium retention in healthy rats
Tekijä: Simona Bussi, et al.
Julkaistu: (2020-02-01)